Loading...

ISR Immune System Regulation Holding

OM:ISR BTA
Snowflake Description

Mediocre balance sheet with weak fundamentals.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
ISR BTA
OM
SEK134M
Market Cap
  1. Home
  2. SE
  3. Pharmaceuticals & Biotech
Company description

ISR Immune System Regulation Holding AB (publ) researches and develops drugs for treatments of viral infections in Sweden. The last earnings update was 152 days ago. More info.


Add to Portfolio Compare Print
  • ISR Immune System Regulation Holding has significant price volatility in the past 3 months.
ISR BTA Share Price and Events
7 Day Returns
-9.1%
OM:ISR BTA
4.4%
SE Biotechs
2.5%
SE Market
1 Year Returns
-
OM:ISR BTA
39%
SE Biotechs
-9%
SE Market
ISR BTA Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
ISR Immune System Regulation Holding (ISR BTA) -9.1% -9.1% - - - -
SE Biotechs 4.4% 6.3% 2% 39% 82.9% 102.2%
SE Market 2.5% 0.8% -3.3% -9% 10% 11.2%
1 Year Return vs Industry and Market
  • No trading data on ISR BTA.
  • No trading data on ISR BTA.
Price Volatility
Industry
5yr Volatility vs Market

Value

 Is ISR Immune System Regulation Holding undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for ISR Immune System Regulation Holding. This is due to cash flow or dividend data being unavailable. The share price is SEK5.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for ISR Immune System Regulation Holding's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are ISR Immune System Regulation Holding's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
OM:ISR BTA PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-06-30) in SEK SEK-0.96
OM:ISR Share Price ** OM (2019-01-08) in SEK SEK5.02
Sweden Biotechs Industry PE Ratio Median Figure of 7 Publicly-Listed Biotechs Companies 58.28x
Sweden Market PE Ratio Median Figure of 318 Publicly-Listed Companies 15.31x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of ISR Immune System Regulation Holding.

OM:ISR BTA PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= OM:ISR Share Price ÷ EPS (both in SEK)

= 5.02 ÷ -0.96

-5.21x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • ISR Immune System Regulation Holding is loss making, we can't compare its value to the SE Biotechs industry average.
  • ISR Immune System Regulation Holding is loss making, we can't compare the value of its earnings to the Sweden market.
Price based on expected Growth
Does ISR Immune System Regulation Holding's expected growth come at a high price?
Raw Data
OM:ISR BTA PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -5.21x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts
Not available
Sweden Biotechs Industry PEG Ratio Median Figure of 7 Publicly-Listed Biotechs Companies 2.14x
Sweden Market PEG Ratio Median Figure of 227 Publicly-Listed Companies 1x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for ISR Immune System Regulation Holding, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on ISR Immune System Regulation Holding's assets?
Raw Data
OM:ISR BTA PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-06-30) in SEK SEK0.33
OM:ISR Share Price * OM (2019-01-08) in SEK SEK5.02
Sweden Biotechs Industry PB Ratio Median Figure of 39 Publicly-Listed Biotechs Companies 5.22x
Sweden Market PB Ratio Median Figure of 557 Publicly-Listed Companies 2.44x
OM:ISR BTA PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= OM:ISR Share Price ÷ Book Value per Share (both in SEK)

= 5.02 ÷ 0.33

15.35x

* Primary Listing of ISR Immune System Regulation Holding.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • ISR Immune System Regulation Holding is overvalued based on assets compared to the SE Biotechs industry average.
X
Value checks
We assess ISR Immune System Regulation Holding's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. ISR Immune System Regulation Holding has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is ISR Immune System Regulation Holding expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as ISR Immune System Regulation Holding has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.

Show me the analysis anyway

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
14.7%
Expected Biotechs industry annual growth in earnings.
Earnings growth vs Low Risk Savings
Is ISR Immune System Regulation Holding expected to grow at an attractive rate?
  • Unable to compare ISR Immune System Regulation Holding's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
  • Unable to compare ISR Immune System Regulation Holding's earnings growth to the Sweden market average as no estimate data is available.
  • Unable to compare ISR Immune System Regulation Holding's revenue growth to the Sweden market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
OM:ISR BTA Future Growth Rates Data Sources
Data Point Source Value (per year)
Sweden Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 14.7%
Sweden Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 23.1%
Sweden Market Earnings Growth Rate Market Cap Weighted Average 9.7%
Sweden Market Revenue Growth Rate Market Cap Weighted Average 4.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
OM:ISR BTA Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (6 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
All numbers in SEK Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
OM:ISR BTA Past Financials Data
Date (Data in SEK Millions) Revenue Cash Flow Net Income *
2018-06-30 -17 -18
2018-03-31 -0 -18 -18
2017-12-31 -21 -21
2017-09-30 -30 -30
2017-06-30 -28 -29
2017-03-31 0 -24 -27
2016-12-31 -18 -22

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Unable to determine if ISR Immune System Regulation Holding is high growth as no earnings estimate data is available.
  • Unable to determine if ISR Immune System Regulation Holding is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
OM:ISR BTA Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (6 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below

All data from ISR Immune System Regulation Holding Company Filings, last reported 6 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

OM:ISR BTA Past Financials Data
Date (Data in SEK Millions) EPS *
2018-06-30 -0.96
2018-03-31 -0.99
2017-12-31 -1.15
2017-09-30 -1.64
2017-06-30 -1.59
2017-03-31 -1.45
2016-12-31

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if ISR Immune System Regulation Holding will efficiently use shareholders’ funds in the future without estimates of Return on Equity.

Next steps:

  1. ISR Immune System Regulation Holding's future outlook can be gauged by looking at industry trends and market size, and determining how well-positioned the company is compared to its competitors. Take a look at other high-growth Pharmaceuticals & Biotech companies here
  2. ISR Immune System Regulation Holding's competitive advantages and company strategy can generally be found in its financial reports archived here.
  3. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Future performance checks
We assess ISR Immune System Regulation Holding's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Sweden market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Sweden market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
ISR Immune System Regulation Holding has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has ISR Immune System Regulation Holding performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare ISR Immune System Regulation Holding's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • ISR Immune System Regulation Holding does not make a profit and there is insufficient past data to establish if their 5 year on year earnings growth rate was positive.
  • Unable to compare ISR Immune System Regulation Holding's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare ISR Immune System Regulation Holding's 1-year growth to the SE Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
ISR Immune System Regulation Holding's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from ISR Immune System Regulation Holding Company Filings, last reported 6 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

OM:ISR BTA Past Revenue, Cash Flow and Net Income Data
Date (Data in SEK Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-06-30 -17.84 5.78
2018-03-31 -0.05 -18.41 5.07
2017-12-31 -21.30 4.44
2017-09-30 -30.35 1.21
2017-06-30 -29.48 1.41
2017-03-31 0.05 -26.84 2.04
2016-12-31 -22.11 2.33

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if ISR Immune System Regulation Holding has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if ISR Immune System Regulation Holding has efficiently used its assets last year compared to the SE Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if ISR Immune System Regulation Holding improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess ISR Immune System Regulation Holding's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
ISR Immune System Regulation Holding has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is ISR Immune System Regulation Holding's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up ISR Immune System Regulation Holding's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • ISR Immune System Regulation Holding is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • ISR Immune System Regulation Holding's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of ISR Immune System Regulation Holding's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 11.4x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from ISR Immune System Regulation Holding Company Filings, last reported 6 months ago.

OM:ISR BTA Past Debt and Equity Data
Date (Data in SEK Millions) Total Equity Total Debt Cash & Short Term Investments
2018-06-30 6.05 0.74 7.42
2018-03-31 6.05 0.74 7.42
2017-12-31 14.89 0.74 15.62
2017-09-30 19.96 0.00 20.57
2017-06-30 23.82 0.00 24.73
2017-03-31 28.50 0.00 29.95
2016-12-31 36.19 1.02 37.38
  • ISR Immune System Regulation Holding's level of debt (12.2%) compared to net worth is satisfactory (less than 40%).
  • Unable to establish if ISR Immune System Regulation Holding's debt level has increased without past 5-year debt data.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • ISR Immune System Regulation Holding has less than a year of cash runway based on current free cash flow.
  • ISR Immune System Regulation Holding has less than a year of cash runway if free cash flow continues to reduce at historical rates of -53.2% each year.
X
Financial health checks
We assess ISR Immune System Regulation Holding's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. ISR Immune System Regulation Holding has a total score of 3/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is ISR Immune System Regulation Holding's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from ISR Immune System Regulation Holding dividends.
If you bought SEK2,000 of ISR Immune System Regulation Holding shares you are expected to receive SEK0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate ISR Immune System Regulation Holding's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate ISR Immune System Regulation Holding's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
OM:ISR BTA Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 0.8%
Sweden Market Average Dividend Yield Market Cap Weighted Average of 243 Stocks 3.8%
Sweden Minimum Threshold Dividend Yield 10th Percentile 1.1%
Sweden Bottom 25% Dividend Yield 25th Percentile 2%
Sweden Top 25% Dividend Yield 75th Percentile 4.9%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as ISR Immune System Regulation Holding has not reported any payouts.
  • Unable to verify if ISR Immune System Regulation Holding's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of ISR Immune System Regulation Holding's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as ISR Immune System Regulation Holding has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess ISR Immune System Regulation Holding's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.1%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can ISR Immune System Regulation Holding afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. ISR Immune System Regulation Holding has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of ISR Immune System Regulation Holding's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
  • ISR Immune System Regulation Holding has no CEO, or we have no data on them.
Management Team
Board of Directors
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (SEK) Value (SEK)
X
Management checks
We assess ISR Immune System Regulation Holding's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. ISR Immune System Regulation Holding has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

External News
Loading...
Simply Wall St News

Company Info

Map
Description

ISR Immune System Regulation Holding AB (publ) researches and develops drugs for treatments of viral infections in Sweden. Its product candidates include ISR048 that is in Phase I/IIa clinical trial for the treatment of human immunodeficiency virus infection (HIV); and ISR049, which is in development stage to treat HIV. The company is headquartered in Stockholm, Sweden.

Details
Name: ISR Immune System Regulation Holding AB (publ)
ISR BTA
Exchange: OM
Founded:
SEK133,649,408
23,122,735
Website: http://israb.se
Address: ISR Immune System Regulation Holding AB (publ)
Rörstrandsgatan 58,
Stockholm,
Stockholm County, 113 40,
Sweden
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
OM ISR Share Capital OMX Nordic Exchange Stockholm SE SEK 24. Mar 2017
OM ISR BTA SHS OMX Nordic Exchange Stockholm SE SEK 10. Dec 2018
Number of employees
Current staff
Staff numbers
0
ISR Immune System Regulation Holding employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/01/14 23:05
End of day share price update: 2019/01/08 00:00
Last earnings filing: 2018/08/15
Last earnings reported: 2018/06/30
Last annual earnings reported: 2017/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.